相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial
Kieran F. Docherty et al.
EUROPEAN JOURNAL OF HEART FAILURE (2023)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
Theresa A. McDonagh et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction
Daniela Tomasoni et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors et al.
NATURE MEDICINE (2022)
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
James L. Januzzi et al.
JACC-HEART FAILURE (2022)
Safety, tolerability, and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
Alexandre Mebazaa et al.
LANCET (2022)
Sequential Evaluation of NT-proBNP in Heart Failure
Paul W. Armstrong et al.
JACC-HEART FAILURE (2022)
Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
Wassim Bedrouni et al.
CIRCULATION-HEART FAILURE (2022)
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
Julio Nunez et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Peder L. Myhre et al.
JACC-HEART FAILURE (2022)
Amended STRONG-HF study design
Gad Cotter et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Jr James L. Januzzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial
Phillip H. Lam et al.
AMERICAN JOURNAL OF MEDICINE (2020)
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction TRANSITION Study
Domingo Pascual-Figal et al.
JACC-HEART FAILURE (2020)
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes
Justin A. Ezekowitz et al.
JACC-HEART FAILURE (2020)
Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction
Benjamin S. Wessler et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations
Christian Mueller et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study
Antoine Kimmoun et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure
Muthiah Vaduganathan et al.
JACC-HEART FAILURE (2018)
NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?)
Susan Stienen et al.
CIRCULATION (2018)
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
Michael R. Zile et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?
Susan Stienen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure A Meta-Analysis
Gianluigi Savarese et al.
JACC-HEART FAILURE (2014)
Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program Correlation With Outcomes
Marco Metra et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Landmark Analysis at the 25-Year Landmark Point
Urania Dafni
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2011)
Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure
Alain Cohen-Solal et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
State of the art: Using natriuretic peptide levels in clinical practice
Alan Maisel et al.
EUROPEAN JOURNAL OF HEART FAILURE (2008)
N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients
P Bettencourt et al.
CIRCULATION (2004)
Effects of initiating carvedilol in patients with severe chronic heart failure - Results from the COPERNICUS study
H Krum et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
EQ-5D: a measure of health status from the EuroQol Group
R Rabin et al.
ANNALS OF MEDICINE (2001)
分享论文
